Welcome to our dedicated page for Vericel SEC filings (Ticker: VCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vericel Corporation (VCEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed issuer, Vericel files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with exhibits and financial statements.
Through these documents, investors can review detailed financial information about Vericel’s business in advanced therapies for sports medicine and severe burn care. The filings describe revenue by product category, including MACI and Burn Care (Epicel and NexoBrid), gross margin, operating expenses, net income or loss, cash and investments, and non-GAAP measures such as adjusted EBITDA. Management explains its use of non-GAAP metrics and provides reconciliations to GAAP results.
Vericel’s Form 8-K filings often furnish press releases announcing quarterly financial results, such as the reports for the quarters ended June 30 and September 30, 2025. These current reports give timely insight into performance trends, business highlights, manufacturing scale-up activities and clinical program updates, including MACI Ankle studies and facility qualification efforts.
Annual and quarterly reports also contain risk factor and forward-looking statement sections that outline uncertainties related to revenue growth, market penetration for MACI, MACI Arthro, Epicel and NexoBrid, manufacturing capacity, reimbursement dynamics, surgeon and burn center adoption, supply chain issues and broader macroeconomic and geopolitical conditions.
On Stock Titan, Vericel’s filings are supplemented with AI-powered summaries that highlight key points from lengthy 10-K and 10-Q documents, explain complex accounting or non-GAAP metrics in plain language, and surface notable items from Form 4 insider transaction reports when available. Real-time updates from EDGAR help users track new VCEL filings as they are posted, while AI-generated overviews make it easier to understand how each filing relates to Vericel’s business in cell therapies and specialty biologics.